论文部分内容阅读
目的探讨胰岛素样生长因子-1(IGF-1)和胰岛素样生长因子结合蛋白-3(IGFBP-3)在乳腺癌中的表达和意义,并研究其与化疗疗效的关系。方法运用酶联免疫吸附法(ELISA)检测32例乳腺癌患者(A组),20例乳腺良性肿瘤患者(B组)和15例健康人(C组)血清中IGF-1和IGFBP-3的含量。结果 A组血清中IGF-1水平为(628.25±124.50)μg/L,B组血清中IGF-1水平为(435.46±116.86)μg/L,C组血清中IGF-1水平为(413.65±104.12)μg/L,A组明显高于B、C组且差异有统计学意义(P<0.05),但B组与C组之间差异无统计学意义(P>0.05)。A、B、C组血清中IGFBP3水平分别为(3596.12±1056.32)μg/L、(3856.12±1142.39)μg/L和(3912.65±1153.14)μg/L,3组之间差异无统计学意义(P>0.05)。15例化疗有效的患者,化疗2周期后IGF-1水平较化疗前明显降低,而IGFBP3水平呈高表达(P<0.05)。结论血清IGF-1和IGFBP-3含量变化有助于乳腺癌的辅助诊断和化疗疗效预测。
Objective To investigate the expression and significance of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in breast cancer and to investigate its relationship with the efficacy of chemotherapy. Methods Serum concentrations of IGF-1 and IGFBP-3 in 32 patients with breast cancer (A group), 20 patients with benign breast tumor (Group B) and 15 healthy individuals (Group C) were detected by enzyme linked immunosorbent assay (ELISA) content. Results The serum level of IGF-1 in group A was (628.25 ± 124.50) μg / L, that in group B was (435.46 ± 116.86) μg / L, and that in group C was (413.65 ± 104.12) ) μg / L, the level of A in group B and C was significantly higher than that in group B and C (P <0.05), but there was no significant difference between group B and group C (P> 0.05). The serum levels of IGFBP3 in groups A, B and C were (3596.12 ± 1056.32) μg / L, (3856.12 ± 1142.39) μg / L and (3912.65 ± 1153.14) μg / L, respectively > 0.05). In 15 patients with chemotherapy, the level of IGF-1 in 2 cycles after chemotherapy was significantly lower than that before chemotherapy, while the level of IGFBP3 was highly expressed (P <0.05). Conclusion The changes of serum IGF-1 and IGFBP-3 levels are helpful for the diagnosis of breast cancer and the prediction of the efficacy of chemotherapy.